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 Advanced glycation end products (AGEs) 
are formed in diverse settings, including 
in association with diabetes, aging, 
hypoxia, ischemia – reperfusion injury, 
renal failure, and infl ammation. Exoge-
nous AGEs are thought be absorbed into 
the circulation from reactions between 
sugars and proteins in foods. Indeed, 
AGE content is high in cooked and pro-
cessed foods, especially those rich in pro-
teins, fats, and glucose. Dietary AGEs are 
considered to be similar to endogenous 
AGEs with regard to their pro-oxidant, 
pro infl ammatory, and signaling proper-
ties. Importantly, the kidney is a target 
organ for AGE-mediated damage and 
also the main contributor to increasing 
circulating AGE concentration, since 
clearance of AGEs is reduced when renal 
function declines. 1 The receptor for 
AGEs (RAGE) was fi rst identifi ed as the 
signal trans duction receptor for AGEs. 
Initially, the role of RAGE in renal dys-
function was studied in diabetes; how-
ever, more recently, RAGE also seems to 
play a role in the pathogenesis of renal 
disorders that are not associated with 
diabetes, such as obesity-related glome-
rulopathy, doxorubicin-induced nephro-
pathy, renal amyloidosis, and ischemic 
renal injuries. 2 
 Epidemiological studies indicated that 
obesity is a risk factor for developing end-
stage renal disease. 3 Obesity leads to a 
form of nephropathy characterized by 
glomerulomegaly. Varying degrees of focal 
segmental glomerulosclerosis and podo-
cyte foot process effacement have also 
been documented in obese individuals, 
albeit to a lesser degree than those 
observed in patients with primary focal 
segmental glomerulosclerosis. 4 
 Th e mechanisms by which obesity pre-
disposes people to kidney damage are 
unknown. Hall  et al. reported that obesity 
increases renal sodium reabsorption and 
impairs pressure natriuresis by the activa-
tion of the renin – angiotensin system and 
the sympathetic nervous system and 
by altered intrarenal physical forces. 5 Fur-
ther, insulin resistance in obese subjects 
was associated with a higher glomerular 
filtration fraction. A greater degree of 
insulin resistance may cause renal injury 
by worsening renal hemodynamics 
through elevation of the glomerular fi ltra-
tion fraction and resultant glomerular 
hyperfi ltration. 6 AGE – RAGE interaction 
may also contribute to the pathogenesis of 
obesity-related renal dysfunction. In an 
animal model, a high-fat diet was associ-
ated with obesity and with elevated serum 
and tissue AGEs, nuclear  O -Glc-Nac 
modifi cation, and apoptosis. 7 Moreover, 
AGEs have direct and indirect actions that 
potentially contribute to insulin resistance 
via oxidative stress generation and chronic 
infl ammation. A form of obesity-related 
glomerulosclerosis has been shown 
to develop in animal models of obesity 
such as the fatty Zucker rat. Long-term 
treatment of fatty Zucker rats with piogli-
tazone inhibited diff use or nodular thick-
ening of the mesangial matrix, atrophy of 
the proximal tubules, thickening of the 
basement membrane of the tubules, and 
mild cellular infi ltration in the stroma. 
Furthermore, pioglitazone inhibited 
increased expression of RAGE and trans-
forming growth factor-  mRNA in the 
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 AGE – RAGE interaction and 
oxidative stress in obesity-
related renal dysfunction 
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 Obesity is a risk factor for development of kidney disease. Advanced 
glycation end products (AGEs) and the receptor for AGEs (RAGE) play 
important roles in the pathogenesis of renal disorders that are not 
associated with diabetes. Harcourt  et al. provide evidence to support the 
mechanism responsible for AGE – RAGE interaction and the downstream 
oxidative stress and inflammation in obesity-related dysfunction. These 
findings might provide a new strategy for kidney disease in obesity. 
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kidneys of fatty Zucker rats. 8 Tanji  et al. 9 
reported expression of AGEs and RAGE 
in diabetic nephropathy and nondiabetic 
renal diseases.  N -(carboxymethyl) lysine 
and pentosidine, which are a subclass 
of AGE, were identifi ed in the areas of 
glomerulosclerosis and arteriosclerosis in 
idiopathic focal segmental glomeruloscle-
rosis and focal sclerosis secondary to 
obesity. On the other hand, expressions of 
podocyte RAGE were indistinguishable 
from those in normal control samples. 9 
 Harcourt  et al. 10 (this issue) present 
studies in which they attempted to lower 
tissue AGE burden in humans and mice 
and studied whether that would improve 
obesity-related renal dysfunction. In the 
human study, a low-AGE diet attenuated 
inflammatory profiles such as urinary 
8-isoprostanes, plasma monocyte chem-
oattractant protein-1 (MCP-1), urinary 
albumin / creatinine ratio, and plasma 
cystatin C levels without changing weight 
loss in obese participants. In an animal 
model, there were some discrepancies 
between treatment with alagebrium, an 
AGE cross-link breaker, and RAGE defi -
ciency. This may be due to different 
actions that interfere with the pathophys-
iological eff ects of AGEs.   
 RAGE   −  /  −   mice consuming a Western-
style diet were obese by week 16 with 
signifi cant increases in epididymal and 
omental adipose depots. However, 
increases in body weight and fat deposi-
tion aft er the Western diet were prevented 
by AGE-lowering therapy. Fasting plasma 
glucose and insulin concentrations were 
increased in  RAGE   −  /  −   mouse strains fol-
lowing consumption of a Western diet, 
but these parameters were signifi cantly 
improved in the obese mice treated with 
alagebrium. Similarly, we previously 
reported that pyridoxamine (K-163), an 
AGE inhibitor that blocks oxidative deg-
radation of the Amadori intermediate in 
the Millard reaction, attenuated glucose 
intolerance and hyperinsulinemia and 
also decreased body weight and fat depo-
sition. Although the mechanism by which 
AGE inhibitors decrease body and adipose 
tissue weight could not be clarifi ed in our 
study, improvements in insulin sensitivity 
and hyperinsulinemia by the antioxidative 
eff ect of pyridoxamine should have some 
benefi cial roles in this phenomenon. 11 
Th ese in turn may indirectly attenuate 
renal oxidative stress and renal function. 
 On the other hand, it is interesting that 
 RAGE   −  /  −   mice were able to show 
improvements in renal hyperfi ltration in 
spite of the increase of body weight and 
plasma insulin levels. Although signifi cant 
improvements were seen in a number of 
structural and pathological parameters, 
such as monocyte chemoattractant factors 
and superoxide production, in  RAGE   −  /  −  
mice, the mechanism of improvement of 
renal hyperfi ltration remains to be eluci-
dated and needs further investigation. 
Alagebrium also improved renal expres-
sion of the inflammatory profile, such 
as MCP-1 and macrophage migration 
inhibitory factor (MIF), mitochondrial 
and cytosolic superoxide, and hyperfi ltra-
tion. However, the question remains 
of why alagebrium did not improve 
urinary albumin / creatinine ratios and 
 N -(carboxymethyl) lysine accumulation in 
the obese kidney whereas RAGE defi ciency 
did. Further, neither the urine 8-isopros-
tane nor the renal MIF expression 
improved in  RAGE   −  /  −   mice, even though 
the plasma MIF levels were increased. 
Th ese observations may be due to a RAGE-
independent pathway of AGEs or lack of 
soluble RAGE in  RAGE   −  /  −   mice. 
 It appears that downstream signaling of 
RAGE is involved in the obesity-related 
renal dysfunction and that interaction 
with RAGE is more eff ective than the AGE 
inhibitors. RAGE binding by AGEs or 
other ligands activates diverse signal 
transduction cascades, including p21 ras , 
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 Figure 1  |  Obesity increases renal sodium reabsorption by activation of vasoactive 
hormones. Insulin resistance in obese subjects was associated with a higher glomerular filtration 
fraction. A higher degree of insulin resistance causes glomerular hyperfiltration. Advanced glycation 
end products (AGEs) contribute to insulin resistance via oxidative stress generation and chronic 
inflammation. RAGE binding by AGEs activates signal transduction cascades and leads to downstream 
consequences including generation of cytosolic and mitochondrial superoxide and activation 
of transcription factors such as nuclear factor-  B (NF-  B). AGE – RAGE induction of NF-  B or other 
pathways contributes to the release of proinflammatory cytokines, such as monocyte chemoattractant 
protein-1 (MCP-1) and macrophage migration inhibitory factor (MIF), and various growth factors. 
Inflammatory cells such as monocytes / macrophages may also contribute to renal damage. The effects 
of AGEs are mediated via several receptors, including the receptor for AGEs (RAGE). 
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p38, p44 / p42, and stress-activated protein 
kinase / c-Jun N-terminal kinase; the Janus 
kinase / signal transducer and activator of 
transcription pathway; and the protein 
kinase C pathway. Signal transduction 
leads to downstream consequences 
including generation of reactive oxygen 
species and activation of transcription fac-
tors such as nuclear factor-  B. AGE –
 RAGE induction of nuclear factor-  B or 
other pathways contributes to the release 
of proinfl ammatory cytokines, and the 
expression of adhesion molecules and 
growth factors such as transforming 
growth factor-  1, vascular endothelial 
growth factor, connective tissue growth 
factor, interleukins-1  and -6, insulin-like 
growth factor-1, platelet-derived growth 
factor, tumor necrosis factor-  , and vas-
cular cell adhesion molecule-1. 1 Infl am-
matory cells such as monocytes / 
macrophages induced by proinfl amma-
tory cytokines may also contribute to the 
renal damage at a later stage of kidney dis-
ease in obesity. Further study is required 
( Figure 1 ). 
 Harcourt  et al. 10 provide evidence to 
support the mechanism responsible for 
AGE – RAGE interaction and their down-
stream oxidative stress and infl amma-
tion in obesity-related dysfunction. It is 
notable that a low-AGE diet improved 
renal function in healthy obese individu-
als in a short period (2 weeks). RAGE is 
a multiligand receptor for AGEs that rec-
ognize a common motif. Similarly, the 
eff ects of AGEs are also mediated via 
several receptors, including RAGE, 
AGE-R1, AGE-R2, AGE-R3, CD36, 
ezrin, radixin, and moesin proteins. 1 
Th erefore, until the physiological prop-
erties of RAGE are clearly understood, it 
is best to adopt a cautious approach when 
future therapeutic strategies involving 
long-term blockade of RAGE or its lig-
ands are considered. 
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 Cystic kidney disease is the most frequent 
genetic cause of end-stage renal disease. 1 
Autosomal dominant polycystic kidney 
disease (ADPKD), the most common 
form of cystic renal disease, results from 
mutations in the genes polycystic kidney 
disease 1 ( PKD1 ) and  PKD2 , which 
encode polycystin-1 (PC-1), a large trans-
membrane protein, and PC-2, a cation 
channel. In ADPKD, new cysts develop 
progressively throughout life, ultimately 
resulting in end-stage renal disease. Th is 
phenotype combined with a dominant 
mode of inheritance has prompted the 
proposal of a  ‘ second-hit ’ hypothesis, 
which suggests that an inherited germline 
mutation combined with a second spon-
taneous somatic mutation results in a 
recessive gene defect on the cellular level. 
Th is in turn may promote clonal expan-
sion of cells, similarly to the two-hit model 
in cancer progression. Parallels between 
cancer progression and cyst development 
also prompted the idea of an involvement 
of the oncogenic WNT /  -catenin signal-
ing pathway in cystic kidney disease. 
 Th e WNT family of secreted glycopro-
teins plays important roles in the control 
of embryonic development and tissue 
regeneration. 2,3 Th e core component of 
the canonical WNT pathway is the 
 WNT /  -catenin signaling in 
polycystic kidney disease 
 Anne  Wuebken 1 , 2 and  Kai M.  Schmidt-Ott 1 , 2 , 3 
 Cystic kidney diseases have been linked to defective WNT signal 
transduction. Perturbations of cystic disease genes cause activation of 
canonical WNT /  -catenin / TCF / Lef1 signaling in model organisms and 
cultured cells. Inappropriate levels of WNT /  -catenin signaling cause 
renal cyst formation in mice. These observations have prompted the 
idea  that an activation of WNT /  -catenin signaling may constitute a 
common causative event in cyst formation. Now this view is challenged 
by key genetic mouse models of cystic kidney disease that do not 
display WNT /  -catenin activity in cyst-lining epithelia. 
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